Stocks and Investing Stocks and Investing
Thu, February 8, 2024

Andreas Argyrides Maintained (ASND) at Buy with Increased Target to $225 on, Feb 8th, 2024


Published on 2024-10-28 08:50:46 - WOPRAI, Andreas Argyrides
  Print publication without navigation


Andreas Argyrides of Wedbush, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $207 to $225 on, Feb 8th, 2024.

Andreas has made no other calls on ASND in the last 4 months.



There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 1 agrees with Andreas's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $116 on, Thursday, November 9th, 2023


These are the ratings of the 3 analyists that currently disagree with Andreas


  • Li Watsek of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $173 on, Tuesday, February 6th, 2024
  • Kelly Shi of "Jefferies" Initiated at Strong Buy and Held Target at $150 on, Wednesday, December 20th, 2023
  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $149 on, Tuesday, December 19th, 2023
Contributing Sources